drugset / Trial / NCT05438329
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Timeline
- Start
- 2022-07-19
- Primary completion
- 2027-08-13
- Completion
- 2027-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DB-1305/BNT325 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |